SIGA Stock News

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conferen

SIGA Technologies <> has partnered with U.K.-based biotech company, Bioarchitech, to study its FDA-approved smallpox therapy, TPOXX (tecovirimat), in pre-clinical trials

Investigating TPOXX® in Combination with Bioarchitech’s Oncolytic Vaccinia Immunotherapy Platform Investigating TPOXX® in Combination with Bioarchitech’s Oncolytic Vaccinia Immunotherapy Platfor

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it wi

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, announced today that it will

Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA ), a commercial-stage pharmaceutical company focused on the health security market, today announced that the European Medicines Agency (EMA) approved SIGA''s Marketing Authorisation Application (MAA) for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration (FDA) in July 2018 under the brand name TPOXX ® . The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The MAA was filed under the centralized application process, which, upon approval, enables sales, including procurement for stockpiling, of oral tecovirimat in all European Union (EU) member states, as well as Norway, Iceland, and Liechtenstein. "We are grateful to the EMA for their hard work leading to approval of tecovirimat, which will enable maximum access to the product throughout Europe for a broader range of uses," said Dr.

Zacks Investment Research upgraded shares of SIGA Technologies (NASDAQ:SIGA) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. The brokerage currently has $8.50 price objective on the stock. According to Zacks, SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design []

Parametric Portfolio Associates LLC raised its stake in SIGA Technologies, Inc. (NASDAQ:SIGA) by 12.5% during the second quarter, HoldingsChannel.com reports. The fund owned 57,982 shares of the companys stock after acquiring an additional 6,462 shares during the quarter. Parametric Portfolio Associates LLCs holdings in SIGA Technologies were worth $364,000 at the end of the most [] The post Parametric Portfolio Associates LLC Buys 6,462 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA) appeared first on ETF Daily News .

Zacks Investment Research downgraded shares of SIGA Technologies (NASDAQ:SIGA) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the []

Siga Technologies Inc. (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Siga Technologies Inc. (SIGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

A number of firms have modified their ratings and price targets on shares of SIGA Technologies (NASDAQ: SIGA) recently: 12/11/2021 – SIGA Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “SIGA Technologies Inc. is applying viral and bacterial genomics and sophisticated computational modeling […] The post Recent Research Analysts’ Ratings Changes for SIGA Technologies (SIGA) appeared first on ETF Daily News .

Millennium Management LLC lifted its holdings in shares of SIGA Technologies, Inc. (NASDAQ:SIGA) by 191.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 124,530 shares of the companys stock after purchasing an additional 81,849 shares during the period. Millennium Management LLCs holdings []

SIGA develops smallpox vaccines. Smallpox has been eradicated.